Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ex-vivo Expanded γδ T Lymphocytes in R/R AML
NCT04008381Phase 1Unknown
- Start
- Sep 2019
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in acute myeloid leukemia (AML). Primary endpoints: Four-months remission rate at 4 months and Number of participants with adverse events at 3 years. Status: unknown.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04008381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04008381.